Vir Biotechnology Files 8-K
Ticker: VIR · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1706431
| Field | Detail |
|---|---|
| Company | Vir Biotechnology, Inc. (VIR) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, regulatory
Related Tickers: VIR
TL;DR
Vir Bio filed a routine 8-K, no major news.
AI Summary
Vir Biotechnology, Inc. filed an 8-K on June 5, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing indicates standard corporate reporting activity for Vir Biotechnology, Inc. and does not appear to disclose new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain any new material information or significant financial disclosures.
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Registrant
- June 5, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Vir Biotechnology, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated by the filing's item information.
When was this 8-K filing submitted?
This 8-K filing was submitted on June 5, 2024.
What is the principal executive office address for Vir Biotechnology, Inc.?
The address of Vir Biotechnology, Inc.'s principal executive offices is 1800 Owens Street, Suite 900, San Francisco, California 94158.
What is the telephone number for Vir Biotechnology, Inc.?
The telephone number for Vir Biotechnology, Inc. is (415) 906-4324.
Does this filing indicate any specific new material events or financial results?
Based on the provided text, this filing primarily serves as a notification of standard reporting items (Regulation FD Disclosure, Financial Statements and Exhibits) and does not explicitly detail any new material events or specific financial results.
Filing Stats: 1,034 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2024-06-05 06:04:32
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value VIR Nasdaq Global Select
Filing Documents
- d819044d8k.htm (8-K) — 28KB
- d819044dex991.htm (EX-99.1) — 55KB
- g819044g0605010059277.jpg (GRAPHIC) — 2KB
- 0001193125-24-154636.txt ( ) — 217KB
- vir-20240605.xsd (EX-101.SCH) — 3KB
- vir-20240605_lab.xml (EX-101.LAB) — 18KB
- vir-20240605_pre.xml (EX-101.PRE) — 11KB
- d819044d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This disclosure, including the press release furnished herewith as Exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "plan," "potential," "aim," "expect," "anticipate," "promising" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir's expectations and assumptions as of the date of this Current Report on Form 8-K. Forward-looking statements contained herein include, but are not limited to, statements regarding the Company's strategy and plans, the potential clinical effects of tobevibart and elebsiran, the potential benefits, safety and efficacy of tobevibart and elebsiran, the timing, nature and significance of data from the Company's multiple ongoing trials evaluating tobevibart and elebsiran, including the SOLSTICE data, the timing of any further releases of data or of any presentations or investor conference calls, the Company's plans and expectations for its chronic hepatitis delta and chronic hepatitis B programs, and risks and uncertainties associated with drug development and commercialization. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by the Company's competitors; changes in expected or existing competition; delays in or disruptions to the Company's business or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes. Dru
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIR BIOTECHNOLOGY, INC. Date: June 5, 2024 By: /s/ Marianne De Backer Marianne De Backer, M.Sc., Ph.D., MBA Chief Executive Officer